



New formula Prematil with Milupan. The latest brainwave from Milupa.

Milupa is the first infant milks manufacturer to produce a formulation for preterm babies that is enriched with $\omega 6$ and $\omega 3$ LCP lipids.

It is widely believed that these lipids are important in promoting normal neurological development.


Furthermore, the ESPGAN committee has commented that the addition of $\omega 6$ and $\omega 3$ LCP lipids to formulae for low birthweight infants is desirable.*



The new Milupa formulation, known as Milupan, represents the most significant recent breakthrough in the field of neonatology, as formerly babies could only obtain

these lipids through their mother's milk.

Milupan is added to Milupa Prematil to provide the essential $\omega 6$ and $\omega 3$ LCP lipids in a balanced ratio similar to mother's milk. This makes our new preterm formula the most complete nutritional product currently available for low birthweight infants.




Our existing preterm formula, Milupa Prematil, is already used in over 60 Special Care Baby Units throughout the country. With our latest brainwave we trust we can now look forward to many more.

milupa
Experts in
Infant Nutrition

For further information on new formula Milupa Prematil with Milupan, write to: Scientific Dept., Milupa Ltd., Milupa House, Uxbridge Road, Hillingdon, Uxbridge, Middlesex UB10 ONE. Telephone: 081-573 9966.

* ESPGAN Committee on Nutrition. Acta Paediatr Scand 1991;80: 887-896.

Are the ills of middle and later life rooted in our early development?



Based on an original embroidery by Dean Design

During the past few years a series of articles, mostly from the Medical Research Council's Environmental Epidemiology Unit at the University of Southampton, has been published in leading medical journals. They set out the evidence that certain adult diseases, including coronary heart disease, stroke and diabetes originate in impaired development during fetal life and infancy. Because of the obvious implications for prevention of some of the commonest diseases in Western society, they have attracted international attention. In this book, Professor David Barker, Director of the Unit, has selected 31 articles that he considers seminal and a comprehensive guide to the development of this important topic. Professor Roger Robinson's introduction summarises and interprets the evidence for non-epidemiologists.

The first chapters describe the origins of the hypothesis in geographical studies in England and Wales. These are followed by a series of studies of men and women in middle and late life whose early growth was recorded at the time. In those who have died, cause of death can be related to early growth. Examination of the living has allowed blood pressure, blood lipid and insulin concentrations, and other measurements to be related to different patterns of early growth. Together, the findings show that early development affects the risk of coronary heart disease, stroke, obstructive lung disease and diabetes at least as strongly as obesity, smoking and other aspects of adult life style.

Fetal and Infant Origins of Adult Disease brings together in one volume a body of work that cannot be ignored

Hardback • Illustrations • Tables • 368 pages • ISBN 0-7279-0743-3

UK £24.95; Abroad £30.00 (BMA members £22.95 or £28.00) including postage, by air abroad



ORDER FORM

British Medical Journal, PO Box 295, London WC1H 9TE.

Please send me _____ copy/ies of FETAL AND INFANT ORIGINS OF ADULT DISEASE

NAME _____
(print clearly)

Membership No _____

ADDRESS _____

Cheque enclosed (made payable to British Medical Journal) £ _____
Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Card No. _____ Exp _____



POSTCODE _____

Signature _____

☐ Please send me a book catalogue

BMJ books are also available from major booksellers or the BMJ bookshop in BMA House. Book tokens accepted (UK only).

Air-Shields: Sweet dreams for all the family



For almost forty years Air-Shields has dedicated its resources to the design and development of Intensive Care equipment specifically for hospital nurseries. They have utilized their full experience and resources to create thermal environments to stabilize and nurture newborns.

C500

Their C500 QT Isolette® Incubator combines proven technology with innovative features to minimise excessive stimulation to the infant while, at the same time, reducing stress to parents and attending staff.

Infant Care

The Infant Intensive Care System is recognised as the comprehensive total care work station, with unparalleled accessibility and effective warming of low birth weight infants. Today, it is the standard of excellence for warming, phototherapy treatment and resuscitation of critically ill infants.

All products come with full service support and comprehensive training from S&W Vickers.

S&W Vickers

**V Vickers
Medical**

Ruxley Corner, Sidecup, Kent DA14 5BL Tel: 081-309 0433 Fax: 081-309 0919
32 Kerse Road, Stirling FK7 7TA Tel: 0786-51602 Fax: 0786-51603
4 Balmoral Business Park, Boucher Crescent, Belfast BT12 6HU Tel: 0232 669266

BMJ Publishing Group

Journals

Annals of Internal Medicine - *monthly*
Archives of Disease in Childhood - *monthly*
British Heart Journal - *monthly*
British Journal of Industrial Medicine - *monthly*
British Journal of Obstetrics and Gynaecology - *monthly*
Clinical Chemistry Research - *monthly*
Contemporary Medicine - *bi-monthly*
Gut - *monthly*
Journal of Clinical Pathology - *monthly*
Journal of Epidemiology and Community Health - *bi-monthly*
Journal of Epidemiology and Infection - *quarterly*
Journal of Internal Medicine - *monthly*
Journal of Neurology, Neurosurgery and Psychiatry - *monthly*
Quality in Health Care - *quarterly*
Sexual Health - *monthly*
Tobacco Control and International Journal - *quarterly*

BMA News Review - *monthly*
British Dental Journal - 22 issues a year
BMJ News - 19 issues a year
British Journal of Anaesthesia - *monthly*
Bulletin of Medical Ethics - 10 issues a year
Current Work in the History of Medicine - *quarterly*
Eye - *bi-monthly*
Health Visitor - *monthly*
Medical History - *quarterly*
Medical History Supplement - *annually*

For full details or a sample copy please contact:
Rachel Armitage, Journals Marketing, BMJ Publishing Group,
BMA House, Tavistock Square, London WC1H 9JR

European Journal of

Pediatrics

Incorporating

Acta Paediatrica Belgica

and

Helvetica Paediatrica Acta

Volume 152 No.2 1993

The pioneers of pediatric medicine 81

Review

Probable role of *Streptococcus pyogenes* in Kawasaki disease
T. Akiyama, K. Yashiro 82

Annotation

Sudden infant death syndrome: the new clothes of the emperor
J. Huber 93

Dermatology

Restrictive dermopathy: a lethal congenital skin disorder
R. Hoffmann, M. Lohner, N. Böhm, J. Leititis, H. Helwig 95

Endocrinology

Acquired growth hormone deficiency due to pituitary stalk transection after head trauma in childhood
C. Yamanaka, T. Momoi, I. Fujisawa, K. Kikuchi, M. Kaji, H. Sasaki, T. Yorifuji, H. Mikawa 99

Systemic effects of insulin-like growth factor-II produced and released from Wilms tumour tissue
Q. Ren-Qiu, T. Ruelicke, S. Hassam, G. K. Haselbacher, E. J. Schoenle 102

Gastroenterology/Hepatology

Asymptomatic autoimmune chronic active hepatitis in a male adolescent
S. Peeters, U. Blecker, J. De Vaick, A. Goossens, M. Hautekeete, G. Devis, Y. Vandenplas 107

Growth/Development

Water turnover of healthy children measured by deuterated water elimination
C. Fusch, E. Hungerland, B. Scharrer, H. Moeller 110

Hematology/Oncology

Clinical neurological findings of children with acute lymphoblastic leukaemia at diagnosis and during treatment
L. Vainionpää 115

Immunology/Allergy

The immune response in iron-deficient young children: effect of iron supplementation on cell-mediated immunity
H. Thibault, P. Galan, F. Selz, P. Preziosi, C. Olivier, J. Badoual, S. Hercberg 120

Infectious diseases

Risk factors for mechanical ventilation in respiratory syncytial virus infection
W. J. E. Tissing, H. A. van Steensel-Moll, M. Offringa 125

Metabolic diseases

Meal-induced thermogenesis in obese children with or without familial history of obesity
C. Maffei, Y. Schutz, L. Zocante, L. Pinelli 128

Relation between genotype and phenotype in Swedish phenylketonuria and hyperphenylalaninemia patients
E. Svensson, U. von Döbeln, R. C. Eismann, L. Hagenfeldt, S. L. C. Woo 132

Low iron stores in infants and children with treated phenylketonuria: a population at risk for iron-deficiency anaemia and associated cognitive deficits
J. L. Bodley, V. J. Austin, W. B. Hanley, J. T. R. Clarke, S. Zlotkin 140

Intellectual performance of children with maple syrup urine disease
C. Hilliges, D. Awiszus, U. Wendel 144

Neonatology

Stable microbubble test for predicting the risk of respiratory distress syndrome: I. Comparisons with other predictors of fetal lung maturity in amniotic fluid
S. Chida, T. Fujiwara 148

Stable microbubble test for predicting the risk of respiratory distress syndrome: II. Prospective evaluation of the test on amniotic fluid and gastric aspirate
S. Chida, T. Fujiwara, M. Konishi, H. Takahashi, M. Sasaki 152

Randomised controlled trial of albumin infusion in ill preterm infants

A. Greenough, E. Emery, M. F. Hird, H. R. Gamsu 157

Maternal haemolysis, elevated liver enzymes and low platelets syndrome: specific problems in the newborn

C. M. Eeltink, R. A. van Lingen, J. G. Aarnoudse, J. B. Derks, A. Okken 160

Meconium aspiration and otitis media in children

L. Jaber, R. Gabriel, P. Merlob 164

Nephrology/Urology

Changing pattern of chronic renal failure and renal replacement therapy in children and adolescents: a 20-year single centre study
K. Schärer, U. Reiss, O. Mehls, N. Gretz, K. Möhring, D. E. Müller-Wiefel, A. Wingen 166

Hip effusion in nephrotic syndrome mimicking septic arthritis

S. Gupta, J. M. Nirmal, C. M. E. Lennox 172

News for the practitioner 173

Letters to the editors

Congenital central nervous system abnormalities, idiopathic hypopituitarism and breech delivery: what is the connection?
M. Maghnie, D. Larizza, I. Zuliani, F. Severi 175

Author's reply

K. Fujita, N. Matsuo 175

Isolation of human herpesvirus-6 from an infant with Kawasaki disease
K. Hagiwara, T. Yoshida, H. Komura, F. Kishi, T. Kaji 176

Ethnic differences in *Helicobacter pylori* infection
U. Blecker, Y. Vandenplas 176

Indexed in *Current Contents*

EJPED 152 (2) 81-176 (1993)
Printed on acid-free paper



Springer International

Subscription information

Volume 151 (12 issues) will appear in 1992. Information about obtaining back volumes and microform editions available upon request.

North America. Annual subscription rate: approx. US \$ 991.00 (single issue price approx. \$ 98.00), including carriage charges. Subscriptions are entered with prepayment only.

Orders should be addressed to:

Springer-Verlag New York Inc.
Service Center Secaucus
44 Hartz Way
Secaucus, NJ 07094, USA
Tel. (201) 348-4033
Telex 023125994
FAX (201) 348-4505

All other countries. Annual subscription rate: DM 1698.00 plus carriage charges; Federal Republic of Germany: DM 21.19 incl. value added tax; all other countries: DM 40.20 ex-

cept for the following countries to which SAL delivery (Surface Airmail Lifted) is mandatory: Japan DM 105.00, India DM 76.20, Australia/New Zealand DM 120.60. Airmail delivery to all other countries is available upon request. Volume price: DM 1698.00, single issue price: DM 169.80 plus carriage charges. Subscriptions can either be placed via a bookseller or sent directly to:

Springer-Verlag
Heidelberger Platz 3, 1000 Berlin 33, FRG
Tel. (0)30/8207-0, Telex 183319
FAX (0)30/8214091

Indications: Treatment of serious infections in adults. **Contraindications:** Patients with known hypersensitivity to the drug or to any of the components. **Warnings:** Patients should be monitored for signs of hypersensitivity reactions. **Precautions:** Patients should be monitored for signs of hypersensitivity reactions. **Adverse Reactions:** Patients should be monitored for signs of hypersensitivity reactions. **Drug Interactions:** Patients should be monitored for signs of hypersensitivity reactions. **How Supplied:** Patients should be monitored for signs of hypersensitivity reactions. **Storage:** Patients should be monitored for signs of hypersensitivity reactions. **USDA:** Patients should be monitored for signs of hypersensitivity reactions. **Other:** Patients should be monitored for signs of hypersensitivity reactions.

- ▶ **Proven clinical efficacy^{1,2}**
- ▶ **92% overall response rate in a wide variety of infections¹**
- ▶ **Side-effects generally mild and transient¹⁻³**

Contra-indication: Hypersensitivity to vancomycin.
Warnings: Caution in patients sensitive to vancomycin.
Man Syndrome is not a contra-indication.
Thrombocytopenia has been reported with vancomycin, especially at higher doses, has times usually recommended. It is advisable to perform haematological studies to be performed during treatment. Liver function tests are advised during treatment. Prolonged renal and auditory function tests in prolonged treatment in renal insufficiency or concurrent and sequential use of neurotoxic or nephrotoxic drugs. However no evidence of toxicity has been seen. Adapt dose in renal impairment (see data sheet). **Use in pregnancy:** Consider the potential risks in pregnancy and lactation. **Interactions:** No evidence of interactions or synergistic toxicity with aminoglycosides.
Side-effects: Generally mild and transient rarely requiring cessation of therapy. The following have been reported:
Local reactions: erythema, local pain, thrombophlebitis.
Allergic: rash, pruritus, fever, bronchospasm, skin hypersensitivity reactions.
Gastro-intestinal: nausea, vomiting, diarrhoea.
Blood: eosinophilia, leucopenia, neutropenia, thrombocytopenia, thrombocytosis. **Liver function:** increases in serum transaminases and/or serum alkaline phosphatase. **Renal function:** transient elevations of serum creatinine. **CNS:** dizziness and headache. **Other:** mild hearing loss, tinnitus, vestibular disorder. **Contraindications:** Not removed by haemodialysis. Treat symptomatically.
Pharmaceutical Precautions: Store below 25°C and protect from heat. Use immediately after reconstitution. See data sheet. **Legal Category:** POM. **Package Contents:** One vial 200mg or 400mg telcainipin, one ampoule 100mg.
NN8 price Targicid 200mg: £26.72. Targicid 400mg: £53.44. **Product Licence Numbers Targicid 200mg:** PL4425/0068. Targicid 400mg PL4425/0068. **Water for injections PL4425/0090.** Date of Last Review September 1992. You must refer to the full data sheet before prescribing Targicid.
References: 1. Lewis PJ et al *J Antimicrob Chemother* 1988; 21 (Suppl. A): 61. 2. Kacet N et al *ibid* (passim).
3. Harding I: data file, Marion Merrell Dow Limited.

MARION MERRELL DOW LTD

Further information including data sheet is available from the licence holder: Marion Merrell Dow Limited, Langside House, Stockley Park, Uxbridge, Middlesex UB11 1SE.
Trademarks: MARION MERRELL DOW, TARGOCO

Flow indicated for neonates

ONCE-A-DAY

TARGOCID[®] IM/IV
(teicoplanin)

Against today's Gram-positive infections